摘要
目的 观察联合用药对慢性乙型肝炎(Chronic Hepatitis B CHB) 的治疗效果。方法 68 例CHB 患者随机分为3 组,干扰素联合无环鸟苷组:α- 干扰素300 万iu 肌注、隔日一次,同时口服无环鸟苷,每次0-4g ,每日3 次,疗程3 个月,甘力欣联合猪苓多糖组:甘力欣50 ml ,静点,每天1 次,猪苓多糖,肌注,每天1 次,3 个月为一个疗程;对照组:予一般护肝治疗。疗程结束检测乙肝病毒标致物。结果 α- 干扰素组与对照组比较,甘力欣组与对照组比较HBeAg 、HBV-DNA 阴转率有显著性差异(P< 0-05) ;α- 干扰素组与甘力欣组比较HBeAg 、HBV- DNA 阴转率无显著性差异(P> 0-05) 。结论 干扰素联合无环鸟苷、甘力欣联合猪苓多糖对HBeAg 、HBV- DNA
Aim To explore the Combination Interferon and Aciclovir in the Treatment of Chronic Hepatitis B(CHB).Method 68 cases diagnosed as CHB were divided into 3 groups randomly Combination Interferon and Aciclovir,Combination Diammonium glycyrrhizinate and polyporus and the control group with routine liver protective drugs orally.Results The clearance rates of HBeAg and HBV DNA in the Interferon and Diammonium glycyrrhizinate group were 63.2% and 55.6%,50.0% and 42.1%respectively,Compared with the control,the clearance rates have significant difference (P<0.05),there were no significant difference between Interferon and Diammonium glycyrrhizinate groups.Conclusion Combination Interferon and Aciclovir,Combination Diammonium glycyrrhizinate and polyporus have a good clearance rates of HBeAg and HBV DNA on the CHB patients.
出处
《胃肠病学和肝病学杂志》
CAS
1999年第3期218-219,共2页
Chinese Journal of Gastroenterology and Hepatology
关键词
干扰素
无环鸟苷
甘力欣
慢性
乙型肝炎
Interferon Aciclovir Diammonium glycyrrhizinate Chronic Hepatitis B